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STRUCTURED ABSTRACT 
Background: Mesothelioma is an aggressive thoracic tumour with a poor 
prognosis.  The only treatment that extends survival is chemotherapy.  However, in 
the UK, up to 50% of patients who are suitable for chemotherapy choose not to 
receive it, opting for active symptom control instead.   
 
Aim: The aim of this study was to describe the characteristics of patients who 
chose active symptom control over chemotherapy and explore their reasons for 
doing so. 
 
Design: A prospective, single-centre observational study.  
 
Methods: 200 consecutive patients with mesothelioma from one UK centre were 
included.  Eligibility for chemotherapy and choice of first-line treatment were 
recorded prospectively.  Patient characteristics and outcomes were compared 
using descriptive statistics, regression analysis and survival analysis.  Reasons for 
choosing active symptom control over chemotherapy were extracted, 
retrospectively. 
 
Results: People who chose active symptom control were older, more likely to be 
female and had worse performance statuses than patients who received front-line 
chemotherapy.  Concern over side effects, the modest survival benefit and previous 
adverse experiences with chemotherapy were reported as reasons for the decision. 
 
Median survival was 13.9 months in the chemotherapy group compared with 6.7 
months in the active symptom control group. 
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Conclusions: This is the first study to describe the characteristics of patients with 
mesothelioma who chose active symptom control over chemotherapy, in the front-
line setting.  Important differences were seen between this group and patients who 
received chemotherapy, although confounding is likely to have affected some 
outcomes. 
 
Future research could use qualitative methods to explore patients’ reasons for 
choosing active symptom control, and to further elucidate the decision-making 
process.  
 
KEY WORDS 
Mesothelioma 
Active symptom control 
Chemotherapy 
Treatment decisions 
Best supportive care  
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INTRODUCTION 
Malignant pleural mesothelioma (MPM) is a universally fatal thoracic tumour with 
limited therapeutic options.[1-4] Chemotherapy is the current standard of care for 
first-line treatment, although the survival benefits are modest [5-7].  In a large 
randomised controlled trial and subsequent report from an expanded access 
program, the combination of cisplatin and pemetrexed demonstrated 
improvements in median survival of up to 4 months, compared with cisplatin 
alone..[5, 6]  More recently the phase III MAPS trial showed that the addition of 
bevacizumab to this regimen extended survival by another 2.7 months, although 
this agent may not be suitable for everyone, and is not universally available.[7]    
Multiple clinical trials are currently underway investigating novel agents, and it is 
anticipated that the future of MPM management will include a greater choice of 
treatment options than is currently available.   
 
Aside from clinical trials, the current alternative to chemotherapy as first-line 
treatment for MPM is active symptom control (ASC).  According to the 2007 British 
Thoracic Society Statement on Mesothelioma, ASC should include regular specialist 
follow-up and appropriate symptomatic treatment, such as analgesia, palliative 
radiotherapy and steroids as required.[1]  In a randomised trial comparing 
mitomycin, vinblastine and cisplatin (MVP) or viorelbine chemoptherapy with ASC, 
patients who received ASC alone had similar quality of life to patients who 
received chemotherapy.[8]  That same trial, which is the only randomised study to 
have compared chemotherapy to active symptom control, also demonstrated no 
survival difference between the two groups.[8] However, the trial was undertaken 
in the pre-pemetrexed era and consequently these results cannot be extrapolated 
to modern chemotherapy regimens.  Whilst the true effect of pemetrexed/cisplatin 
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chemotherapy versus no treatment is currently unknown, it is highly likely to 
exceed the 6 months survival benefit conferred by adding pemetrexed and 
bevacizumab to cisplatin.[5, 7]    
 
Patients are considered eligible for first-line chemotherapy if they have a WHO 
performance status (PS) of 0 or 1 and no significant comorbidities.[2, 9, 10] 
Additionally, some patients who have a PS of 2 may be suitable to receive 
chemotherapy, based on individual assessment of their physical health.[9]  In our 
centre, patients with MPM are discussed at a regional mesothelioma 
multidisciplinary team meeting (MDT), where the diagnosis is confirmed and 
eligibility for chemotherapy determined.[11]  Eligible patients are offered first-line 
chemotherapy at their subsequent clinic appointment with their treating 
respiratory physician and given the chance to discuss the benefits and 
disadvantages of the planned treatment regimen with that clinicain.  Participants 
who wish to receive chemotherapy, or who wish to consult with an oncologist to 
discuss the matter further, are referred to an oncologist.  Patients who state at the 
outset that they do not wish to receive chemotherapy are not referred to an 
oncologist. 
 
A proportion of patients who are offered first-line chemotherapy make an 
informed decision to receive ASC instead.  Epidemiological data collected in Leeds, 
UK between 2001 and 2005 reported that 28 out of 54 eligible patients (52%) 
declined chemotherapy.[12]  More recently, the UK National Lung Cancer Audit 
revealed that chemotherapy uptake in MPM patients with PS 0-1 varied from 46% 
to 71% across UK centres.[2]  Given that the majority of these patients would have 
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been eligible to receive front-line chemotherapy, it is likely that a proportion of 
them made an active decision to receive ASC instead. 
 
Epidemiological data from other countries is difficult to interpret, as performance 
status and eligibility for chemotherapy is often omitted.  However, Kao et al 
proposed an optimal chemotherapy utilization rate of 65% based on predictions of 
eligibility.[13]   Chemotherapy usage rates of 36% in the Netherlands between 
2005 and 2006, and 54% in Australia between 2007 and 2009 are both lower than 
this proposed benchmark, again suggesting that a proportion of patients chose not 
to receive chemotherapy despite being eligible.[14, 15]  
 
The aim of this study was to explore the characteristics of patients who chose to 
receive ASC rather than first-line chemotherapy, and to determine what factors 
were associated with this decision.  This information is important, as a treatment 
will only be effective if patients are willing to take it.   Similarly, a new treatment 
may demonstrate encouraging results in clinical trials, but its effectiveness will be 
reduced if, in real-life, patients chose not to receive it.  This is likely to become 
increasingly pertinent as new treatments emerge for mesothelioma and become 
adopted into usual clinical care. 
 
Acknowledging there is a cohort of patients who decline first-line chemotherapy, 
recognising their characteristics, and exploring their reasons for making this 
choice may help improve treatment uptake in the future.  Additionally, this 
information will afford clinicians and allied health professionals a greater 
understanding of their patients, and will lead to better communication, particularly 
in discussions related to treatment decisions and chemotherapy.   
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METHODS 
This was a prospective, observational, single-centre, UK-based study of 
consecutive patients with MPM enrolled in an ongoing prospective cohort study 
(Investigating Pleural Disease Study, Central Bristol REC approval 08/H0102/11 – 
see Appendix 1 for inclusion and exclusion criteria). All patients with a diagnosis of 
MPM were included, and all diagnoses of MPM were discussed and confirmed at 
the regional MPM MDT. 
 
Baseline characteristics, symptoms and tumour variables (histological sub-type 
and IMIG stage[16]) were collected prospectively.  Eligibility for first-line 
chemotherapy was determined at MDT and subsequently confirmed on an 
individual basis in oncology or respiratory clinics.  Patients were considered 
eligible for front-line chemotherapy if they had a PS of 0 or 1 and no significant 
organ dysfunction (e.g. cardiac, renal or liver), or if they had a PS of 2 with good 
physical function and few co-morbidities.   
 
The primary outcome was the proportion of patients who chose to receive ASC 
having been offered first-line chemotherapy.  This decision was recorded 
prospectively on the study database.  Patients’ reasons for choosing ASC were 
obtained from retrospective interrogation of medical records and clinic letters.  
Potential reasons for choosing ASC were not defined a priori, as this was 
considered a hypothesis generating exercise. 
 
The characteristics of patients who were offered first-line chemotherapy and chose 
ASC were compared with patients who accepted first-line chemotherapy.  Chi 
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squared test was used for categorical variables, with Fishers Exact test employed if 
any individual value was less than 10.  Unpaired two-tailed T tests were used for 
normally-distributed continuous variables and Wilcoxon Rank Sum for non-
parametric continuous data.  Univariable and multivariable logistic regression was 
used to explore associations between baseline characteristics and choosing ASC. 
 
The secondary outcome was survival, calculated from date of diagnosis to date of 
death, censored on 26/06/2017.  Survival was calculated for all MPM patients who 
were offered chemotherapy.  Survival in patients who were offered first-line 
chemotherapy and chose ASC was compared with patients who accepted first-line 
chemotherapy.  Kaplan Meier curves were drawn to visually compare survival 
between these two groups.  Cox Proportional Hazards model was used, with 
adjustment for age, sex, laterality, PS, histology, stage and symptoms. 
 
Apart from patients’ reasons for choosing ASC, all data were collected 
prospectively on the study database.  Relevant data was extracted from the 
database by one of the authors (ACB) using a standardised data collection form 
(shown in Appendix 2).  Patients’ reasons for choosing ASC were obtained 
retrospectively from patient records. 
 
RESULTS 
200 patients with MPM enrolled in the study between 1/3/08 and 8/6/16, of 
whom 150/200 (75%) were considered eligible for first-line chemotherapy at 
initial assessment.  10/150 (6.7%) subsequently became ineligible due to a rapid 
deterioration in PS between baseline assessment and discussion about 
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chemotherapy.  Data were missing on 1 patient who moved out of the area, and 
was lost to follow up.  This person’s data are not included in the analysis. 
 
Primary outcome 
Of 139 patients offered first-line chemotherapy, 93 (66.9%) accepted and 46 
(33.1%) chose ASC.   The characteristics of these patients are shown in Table 1.   
 
The group that chose ASC were older than those who accepted chemotherapy 
(mean age 74.4 vs 68.4, p<0.001) and consisted of a higher proportion of females 
(23.9% vs 10.8%, p=0.041).  Additionally the group that chose ASC had worse PS 
than the group that chose chemotherapy, with fewer PS 0 patients (17.4% vs 
43.0%) and more PS 1 (69.6% vs 51.6%) and PS 2 patients (13.0% vs 5.4%, 
p=0.005).  There was no difference in laterality, histology, stage, symptoms or 
blood tests between the groups.  Of the patients who chose ASC, all 46 received 
their diagnosis from a respiratory physician, with whom they were involved in a 
discussion about first-line chemotherapy.  22/46 (47.8%) stated their decision to 
pursue ASC to the respiratory physician and consequently were not seen by an 
oncologist.  24/46 (52.2%) consulted with both respiratory physician and 
oncologist before deciding to pursue ASC. 
 
In multivariable logistic regression analysis, the factors independently associated 
with choosing ASC were age (p<0.001) and PS (p=0.024).    
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Table 1 - Characteristics of patients who were offered first-line chemotherapy, who 
chose ASC or chemotherapy 
ASC= active symptom control SD=standard deviation, IQR=interquartile range 
 
 
 Received 
chemotherapy 
Chose 
ASC   
p 
 
Total (n=139) 
 
93 (66.9) 
 
46 (33.1) 
 
Sex, n (%) 
Male 
Female 
 
 
83 (89.2) 
10 (10.8) 
 
35 (76.1) 
11 (23.9) 
 
 
 
0.041 
Laterality, n (%) 
Right  
Left 
 
 
54 (58.1) 
39 (41.9) 
 
 
27 (58.7) 
19 (41.3) 
 
 
 
0.943 
Age, mean (SD) 
 
 
68.4 (6.36) 
 
74.4 (7.35) 
 
<0.001 
Performance status, n (%) 
0 
1 
2 
 
 
40 (43.0) 
48 (51.6) 
5 (5.4) 
 
8 (17.4) 
32 (69.6) 
6 (13.0) 
 
 
 
 
 
0.005 
Histology, n (%) 
Epithelioid 
Sarcomatoid 
Biphasic 
Desmoplastic 
Not specified 
 
63 (67.7) 
15 (16.1) 
9 (9.7) 
2 (2.2) 
4 (4.3) 
 
36 (78.3) 
6 (13.0) 
1 (2.2) 
1 (2.2) 
2 (4.4) 
 
 
 
 
 
 
0.540 
IMIG tumour stage, n (%) 
IA 
IB 
II 
IIIA 
IIIB 
IV 
Not documented 
28 (30.1) 
6 (6.5) 
7 (7.5) 
0  
30 (32.2) 
10 (10.75) 
12 (12.9) 
15 (32.6) 
0 
3 (6.5) 
0 
13 (28.2) 
7 (15.2) 
8 (17.4) 
 
 
 
 
 
 
 
 
0.543 
Symptoms, n (%) 
Chest pain 
Breathlessness 
Cough 
Systemic symptoms  
(sweats, weight loss, fatigue) 
 
38 (40.9) 
75 (80.7) 
42 (45.1) 
37 (39.8) 
 
22 (47.8) 
39 (84.8) 
18 (39.1) 
22 (47.8) 
 
0.435 
0.550 
0.499 
0.367 
 
Blood tests, median (IQR) 
Haemoglobin, g/dL 
Neutrophils, x109/L 
Lymphocytes, x109/L 
Albumin, g/L 
Neutrophil Lymphocyte Ratio (NLR) 
 
138 (126-150) 
5.73 (4.80-7.00) 
1.6 (1.15-2.15) 
35 (31-38) 
4.00 (2.73-5.38) 
 
132.5 (121-149) 
5.84 (4.28-7.00) 
1.32 (1.00-1.94) 
34 (30-38) 
4.18 (3.09-6.38) 
 
0.263 
0.729 
0.076 
0.456 
0.255 
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Patients’ reasons for choosing ASC over first-line chemotherapy were documented 
in 15/46 (32.6%) cases.  Reasons included concern that the benefits of 
chemotherapy did not justify the risk of side effects (5/15), a desire to prioritise 
quality of life in the context of no current symptoms (4/15), needle or hospital-
phobia (3/15) and pursuit of alternative, experimental treatment in another 
country (1/15).  Two (2/15) patients reported previous negative experiences with 
chemotherapy as their reason for choosing ASC.  One of these patients had 
received chemotherapy for previous ovarian cancer, whilst the other had cared for 
his brother whilst he received chemotherapy for lung cancer. 
 
Secondary outcome – survival 
Median survival for all 139 MPM patients who were eligible for chemotherapy was 
13.1 months (interquartile range (IQR) 7.3 – 20.0 months).  Median survival in 
patients who received first-line chemotherapy was 14.5 months, compared with 
9.8 months in patients who chose ASC having been offered first-line chemotherapy 
(hazard ratio (HR) 0.59, 95% CI 0.40 – 0.87, p=0.007).  Kaplan Meier survival 
curves are shown in Figure 1. 
 
In multivariable cox regression analysis, factors independently associated with 
poor survival were PS of 2  (HR 2.45, 95% CI 1.09-5.50, p=0.03), non-epithelioid 
histology (HR 1.79, 95% CI 1.16-2.76, p=0.009), stage (HR 1.21, 95% CI 1.09-1.34, 
p<0.001), breathlessness at diagnosis (HR 1.90, 95% CI 1.02-3.50, p=0.042) and 
not receiving chemotherapy (HR 1.86, 95% CI 1.15-2.99, p=0.011). 
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Figure 1 - Kaplan Meier curves comparing survival in patients who chose ASC with 
those chose chemotherapy  
 
 
DISCUSSION 
This is the first study to report the characteristics of patients with MPM who were 
offered first-line chemotherapy but declined it in favour of ASC. In this prospective 
study of 139 patients, significant differences were observed between people who 
chose ASC and those who chose chemotherapy.  This is an important finding in 
understanding attitudes to treatment in MPM, and potential factors affecting 
treatment decisions.  Further research is needed to explore patient’s motivations 
for choosing ASC in greater depth, and the use of qualitative research methods 
could provide rich and informative data on this subject.   
 
A strength of this study is the lack of missing data.  Apart from one patient who 
moved out of the region, treatment choice and survival data was available for all 
patients.  Data on tumour stage and histology was not recorded for a proportion of 
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patients; but this is a phenomenon that has been observed nationally.[2]  Overall, 
however, data completeness was high for this cohort, and this is likely to be a 
result of prospective data collection and rigorous database management.   
 
Patients’ reasons for choosing ASC were collected retrospectively, and 
consequently were only available for one third of participants.  Missing data is a 
recognised limitation of retrospective data collection, and may have introduced 
bias in this domain.   It is acknowledged that the reasons for declining 
chemotherapy reported in this paper may not be representative of the whole 
group and that alternate reasons, not reported here, may also exist.  Given the 
semi-qualitative nature of this outcome measure, results should be seen as 
hypothesis-generating, rather than conclusive.  However, future studies would 
benefit from prospective collection of this information.   
 
This study describes patients seen at a single UK centre and the results may not be 
generalizable.  However, many of the findings from this study replicate other 
observational MPM studies. The male preponderance, the higher incidence of 
right-sided disease and the predominance of epithelioid sub-type are consistently 
reported, and are reproduced here.[2, 3, 9] Additionally the proportion of patients 
who were eligible for first-line chemotherapy, and the percentage of those people 
who went on to receive it were consistent with national rates, suggesting practice 
at our centre is similar to other centres in the UK.[2, 9]  Finally, median survival of 
all MPM patients was comparable to previously reported survival times for 
MPM.[2-4, 9]  The similarities between our cohort and national data suggest that 
patients in this study are representative of MPM patients in general. However, it is 
not known whether the characteristics of patients who choose ASC are the same in 
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other centres.  Further studies are needed to see whether similar results are 
observed elsewhere. 
 
There was a difference in median survival of 7.2 months between patients who 
chose ASC and those who received first-line chemotherapy.  Although no study has 
ever compared cisplatin and pemetrexed chemotherapy with ASC, it is likely that 
this survival difference represents more than just the biological effect of 
chemotherapy.  Confounding due to the non-randomised, observational study 
design will have influenced survival, in that patients who chose ASC had worse 
prognostic features, such as increased age and poorer PS.  Additionally, 
unmeasurable factors may have contributed.  For example, patients who chose ASC 
may have been less likely to seek medical help for other (treatable) medical 
problems, which could have impacted on their overall survival.   
 
Where reasons for choosing ASC were given, they were varied and included 
concerns about chemotherapy side-effects and appreciation of the limited benefit 
offered by current first-line chemotherapy agents.  Causal relationships cannot be 
assumed on the basis of this observational study.  However, it may be that patients 
who were older and frailer had greater concerns about chemotherapy toxicity and 
were consequently more likely to choose ASC.  Qualitative interviews around 
patients’ reasons for choosing ASC would be valuable in exploring this possibility 
in greater detail.  Qualitative methods could also describe other potential reasons 
for choosing ASC or declining chemotherapy, and could reveal important factors in 
the decision-making process.  
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Several of the reasons given by patients for declining chemotherapy in this study 
have been reported in other studies of older adults with cancer, including concern 
about side effects, the wish to prioritise quality of life, and previous negative 
treatment experiences.[17]  Additional reasons for declining cancer treatment that 
have been reported in the literature include low mood and fear of becoming a 
burden on others/losing independence.[17]  These factors were not reported in 
our cohort, but neither were they actively enquired about, due to retrospective 
data collection.  Since none of the existing literature focuses specifically on people 
with mesothelioma, these are important areas that could be explored in future 
research in this patient group.  Further factors affecting decision making around 
cancer treatments include financial considerations and transportation 
difficulties.[17]  Whilst these issues may be less relevant in the UK where the NHS 
provides free universal healthcare, and hospital transportation is readily available, 
they may still be worth including in future prospective and qualitative research.     
 
An important point to be considered in the interpretation of this study is the 
interaction between clinician and patient when discussing treatment options.  It is 
possible that conversations regarding oncological treatments were more 
circumspect in older patients with poorer performance status, and that this 
influenced patient’s decisions.  Clinician’s preferences, whether conscious or sub-
conscious, implicit or explicit, could have affected the dynamic of the consultation 
and swayed patients towards ASC.  An ethnographic, observational approach, or 
detailed conversation analysis, could be employed to investigate this possibility. 
 
This study has highlighted the heterogeneity of patients with MPM, and identifies a 
specific sub-set of patients who choose not to have first-line chemotherapy.  
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Further research is warranted to determine whether these findings are replicated 
in other centres and, indeed, other countries.  Exploring patients’ attitudes to 
chemotherapy, and understanding the factors affecting the decision-making 
process could be the first step towards increasing treatment uptake, and 
potentially improving survival for MPM in the future. 
 
CONCLUSION 
This is the first study to describe the characteristics of patients with mesothelioma 
who chose ASC over front-line chemotherapy.  In this single-centre, UK-based 
study, participants who chose ASC were older, more likely to be female, and had 
worse performance status than those who accepted chemotherapy.  Recognising 
these patients and understanding their motivations could improve communication 
and enhance the relationship between clinicians and patients.   
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APPENDIX 1 – Inclusion and exclusion criteria for the Investigating Pleural Disease 
study 
 
Inclusion criteria: 
1/. Undiagnosed/malignant pleural effusion or pleural thickening requiring 
investigation. 
and 
2/. Pleural aspiration or CT scan form part of the clinical plan. 
Or 
3/. Patients with a confirmed diagnosis of mesothelioma 
 
Exclusion criteria:  
1/. Inability to give informed written consent 
2/. Pregnancy or lactation 
3/. Declines follow up to diagnosis or 12 months. 
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APPENDIX 2 – Data collection form 
 
Participant ID:  
Gender: Male Female 
Age at diagnosis:  
Date of diagnosis:  
Co-morbidities 
Cardiac Yes No 
Renal Yes No 
Other Yes No 
What other?  
Symptoms at presentation 
Chest pain Yes No 
Breathlessness Yes No 
Cough Yes No 
Fatigue Yes No 
Sweats Yes No 
Weight loss Yes No 
Performance 
status 
0 1 2 3 4 
Referred by: GP Resp team 
Ward/ 
inpatient 
MAU 
Other 
hospital 
Biopsy method VATS LAT CT guided US guided Unknown 
Histological sub-
type: 
Epithelioid Sarcomatoid Biphasic Desmoplastic NOS 
Laterality Left Right Not stated 
TNM stage  
IMIG stage Ia Ib II III IV 
Not 
stated 
Bloods at diagnosis 
Haemoglobin  
Neutrophils  
Lymphocytes  
Neut/lymph ratio  
Albumin  
Eligible for chemo Yes No 
Discussed with? Pulmonologist  Oncologist 
Treatment 
decision 
Chemo ASC 
Reason for 
choosing ASC 
 
Outcome Died Censored 
Survival (months)  
 
